Skip to main content
. 2023 Sep 19;129(10):1667–1678. doi: 10.1038/s41416-023-02430-8

Fig. 1. Cisplatin-resistant neuroblastoma cells display a shift in response to BH3-mimetics.

Fig. 1

a IMR-32, Lan5, NLF or SH-SY5Y neuroblastoma cell lines were treated with different concentrations of the BH3-mimetics ABT199, A1331852 or S63845 for 72 h before analysis of viability using CTG assay. The response of parental cells (solid lines) was compared to the response of CDDP-resistant cells (dashed lines). Data shown are mean + standard deviation (SD) with n = 3–4. *p < 0.05, **p < 0.01, ***p < 0.001. Parental or CDDP-resistant SH-SY5Y cells were treated with the clinically tested MCL1 inhibitors S64315 (b) or AZD-5991 (c) for 72 h before analysis of viability using CTG assay. Data shown are mean + SD (n = 3), *p < 0.05, **p < 0.01, ***p < 0.001.